Telmisartan reverses hepatic steatosis via PCK1 upregulation: A novel PPAR-independent mechanism in experimental models of MASLD

Telmisartan reverses hepatic steatosis via PCK1 upregulation: A novel PPAR-independent mechanism in experimental models of MASLD

Drug combination and repurposing are potential therapeutic strategies for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD). Here, we have demonstrated that, in rats, both pemafibrate and telmisartan reverse hepatic steatosis induced by a high-fat, high-fructose diet....

Full description

Saved in:
Bibliographic Details
Main Authors: Roger Bentanachs, Patricia Ramírez-Carrasco, Bianca Braster, Anastasia Emmanouilidou, Endrina Mujica, Maite Rodrigo-Calvo, Cristina Rodríguez, Núria Roglans, Marcel den Hoed, Juan C. Laguna, Marta Alegret
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Pharmacological Research
Subjects:
Liver steatosis
PPAR
Angiotensin receptor blockers
Metabolomics
Phosphoenolpyruvate carboxykinase 1
Gluconeogenesis
Online Access:http://www.sciencedirect.com/science/article/pii/S1043661825002853
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S1043661825002853

Similar Items